divergent-paired related homeobox pseudogene 1Genealiases: []
Q-omics provides the consensus-scored DPRXP1 profile across patient tissues and cancer cell-line models. DPRXP1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LAML. Among the 18 cancer types available for tumor–normal comparison, DPRXP1 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, DPRXP1 RNA expression shows 11,114 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LAML, LUSC, and LSCC as cancer lineages where DPRXP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPRXP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPRXP1 survival associations across molecular data types. DPRXP1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPRXP1 RNA expression–survival associations across cancer types. High DPRXP1 expression shows unfavorable associations in READ, ESCA, TGCT, CHOL and SKCM, but favorable associations in LAML. The LAML Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LAML as the clearest survival context for DPRXP1 RNA expression.
This table summarizes DPRXP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for DPRXP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPRXP1 shows lower tumor expression in LIHC and higher tumor expression in LUSC and STAD. The LUSC box plot shows higher DPRXP1 RNA expression in tumor versus normal tissue (log2 FC = +0.180, t-test p = .036).
This table shows molecular features associated with DPRXP1 in patient tissues and cancer cell lines. In patient samples, DPRXP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
